Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05923671
Other study ID # 1399
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 5, 2020
Est. completion date December 1, 2022

Study information

Verified date June 2023
Source Aristotle University Of Thessaloniki
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this observational study is to compare the composition of the human gingiva in different gingival phenotypes. The main questions to answer are: - Is there any difference in the cellular composition of the gingiva between thin and thick gingival phenotype? - Is there any difference in the molecular composition of the gingiva between thin and thick gingival phenotype? The participants were divided in two groups (thin and thick phenotype) and a biopsy of healthy gingiva was obtained from each one them. The biopsies were analyzed histologically and the collected data will be analyzed statistically in order to identify possible differences between the gingival phenotypes.


Description:

Healthy volunteers were assigned in one of two groups: - Group 1: Thin gingiva, when the free gingiva was evaluated as transparent, after the insertion of a periodontal probe (Hu-Friedy XP-23/QW, Hu-Friedy,Chicago,IL,USA) in the middle of the facial dentogingival sulcus of a maxillary central incisor - Group 2: Thick gingiva: when the free gingiva was evaluated as non-transparent, using the same methodology. A full thickness sample of the oral mucosa of each one of the participants was collected under local anaesthesia. The sample had a rectangular shape, with a length of 4 millimeters and a width of 1 millimeter. It had a vertical orientation and it was expanding at the both sides of the mucogingival junction. The oral mucosa samples were processed for histological and immunohistochemical analysis. Staining with haematoxylin-eosin was performed in order to describe the tissue histologically and also calculate the total number of the cells it contained. Immunohistochemical staining with anti-Vimentin,anti-Cluster of Differentiation 68, anti-Ki-67 and anti-Smooth Muscle Actin antibodies was applied for the calculation of the numbers of fibroblasts, macrophages, Ki-67-positive cells and Smooth muscle actin positive cells respectively. Immunohistochemical staining was also performed in order to determine the levels of expression of Collagen I, Collagen V, Elastin and Hyaluronic acid. Whole slide images of the specimens were acquired with the use of the NanoZoomer 2.0HT (Hamamatsu Pho-tonics K.K., Hamamatsu, Japan). Cell counting will be performed automatically using an image analysis software (QuPath 3.0). The levels of molecular expression will be assessed with the use of the same software and will be expressed as a percentage of the area of the connective tissue that is occupied by the investigated molecules.


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date December 1, 2022
Est. primary completion date December 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Healthy adults Exclusion Criteria: - Attachment loss or Probing depths greater than 2 millimeters at the maxillary central incisors - Altered passive eruption of the maxillary incisors - Previous surgery or orthodontic treatment in the anterior maxilla - Medical conditions or medication affecting soft tissue metabolism - Tooth crowding or abnormal angulation or abrasion of the maxillary incisors - Restorations at the buccal surface of the maxillary central incisors - Smoking - Pregnancy or lactation

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Histological analysis
Histological staining of gingival biopsies with haematoxylin-eosin.
Immunohistochemical analysis
Immunohistochemical staining of gingival biopsies using anti-Vimentin, anti-Collagen I, anti-Collagen V, anti-Elastin, anti-Hyaluronic acid, anti-Smooth muscle actin, anti-Cluster of Differentiation 68 and anti-ki67 antibodies.

Locations

Country Name City State
Greece Aristotle University of Thessaloniki Thessaloniki Macedonia

Sponsors (2)

Lead Sponsor Collaborator
Aristotle University Of Thessaloniki Umeå University

Country where clinical trial is conducted

Greece, 

Outcome

Type Measure Description Time frame Safety issue
Other Keratinized tissue width The length (millimeters) of the line that connects the mucogingival junction and the gingival margin, at the middle of the facial surface of the maxillary central incisor Baseline
Other Gingival thickness The thickness (millimeters) of the gingiva, measured with an ultrasonic biometer (PIROP Biometric scanner, ECHO-SON S.A., Poland) at the middle of the line that connects the mucogingival junction and the gingival margin, at the middle of the facial surface of the maxillary central incisor Baseline
Primary Cell density The number of all types of cells per square millimeter of the connective tissue Baseline
Secondary Fibroblast Density The number of fibroblasts per square millimeter of the connective tissue Baseline
Secondary Macrophage Density The number of macrophages per square millimeter of the connective tissue Baseline
Secondary Density of Ki-67-positive cells The number of Ki-67-positive cells per square millimeter of the connective tissue Baseline
Secondary Density of Smooth Muscle Actin positive cells The number of Smooth Muscle Actin positive cells per square millimeter of the connective tissue Baseline
Secondary Collagen I area ratio The percentage of the area of the connective tissue which is occupied by Collagen I Baseline
Secondary Collagen V area ratio The percentage of the area of the connective tissue which is occupied by Collagen V Baseline
Secondary Elastin area ratio The percentage of the area of the connective tissue which is occupied by Elastin Baseline
Secondary Hyaluronic acid area ratio The percentage of the area of the connective tissue which is occupied by Hyaluronic acid Baseline
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1